There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and Outset Medical (OM – Research Report) with bullish sentiments.
Invest with Confidence:
Gilead Sciences (GILD)
In a report released today, Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences, with a price target of $115.00. The company’s shares closed last Wednesday at $93.04, close to its 52-week high of $98.90.
According to TipRanks.com, Yee ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.1% and a 40.3% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Viridian Therapeutics, and ALX Oncology Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $99.29 average price target, representing a 7.2% upside. In a report issued on January 10, Morgan Stanley also upgraded the stock to Buy with a $113.00 price target.
See today’s best-performing stocks on TipRanks >>
Outset Medical (OM)
In a report released today, Marie Thibault from BTIG maintained a Buy rating on Outset Medical, with a price target of $3.00. The company’s shares closed last Wednesday at $0.78, close to its 52-week low of $0.44.
According to TipRanks.com, Thibault is a 3-star analyst with an average return of 2.5% and a 38.7% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.
Currently, the analyst consensus on Outset Medical is a Strong Buy with an average price target of $3.75.
Read More on GILD: